公开(公告)号：US20210292386A1

公开(公告)日：2021-09-23

申请号：US17262097

申请日：2019-07-19

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON - Translationale Onkologie an der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz

发明人： Ugur Sahin ,  Mathias Vormehr ,  Lena Mareen Kranz ,  Sina Fellermeier-Kopf ,  Alexander Muik ,  Friederike Gieseke ,  Bodo Tillmann ,  Sonja Witzel

IPC分类号： C07K14/55 ,  A61P35/00 ,  A61K45/06 ,  A61K38/20 ,  A61K39/00 ,  A61K39/39

摘要： The invention relates to variants of interleukin-2 (IL2). In one embodiment, the IL2 variants activate effector T cells over regulatory T cells. In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted at at least a position having an acidic or basic amino acid residue in wild type human IL2 that contacts the alpha subunit of the αβγ IL2 receptor complex (I12Kαβγ). Alternatively, the mutein of human IL2 or of a functional variant of human IL2 comprises at least (i) one or more amino acid substitutions which reduce the affinity for the alpha subunit of II_2Kαβγ and (ii) one or more amino acid substitutions which enhance the affinity for II_2Kβγ. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

公开(公告)号：US20210113606A1

公开(公告)日：2021-04-22

申请号：US16966422

申请日：2019-02-08

申请人： BioNTech RNA Pharmaceuticals GmbH ,  TRON - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg-Universität Mainz

发明人： Ugur Sahin ,  Lena Kranz ,  Mathias Vormehr ,  Mustafa Diken ,  Sebastian Kreiter ,  Bodo Tillmann

IPC分类号： A61K31/7105 ,  C07K14/55 ,  C07K14/54 ,  A61K39/00

摘要： The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising co-administering to the subject RNA encoding peptides or proteins used for vaccination and RNA encoding IL-2 attached to a pharmacokinetic modifying group and/or RNA encoding IL-7 attached to a pharmacokinetic modifying group. The vaccine is particularly effective if an immune checkpoint inhibitor such as an anti-PD-L1 antibody is further administered. The present disclosure further relates to methods involving the target-specific delivery of a cytokine to a target organ or target tissue.